BioNano Genomics, Inc. (BNGO)
Stock Price Chart
Key Info
| Market Cap | 76.13M |
| Revenue (ttm) | 7.30M |
| Net Income (ttm) | -37.28M |
| Shares Out | 132.94M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $0.497 |
| Previous Close | $0.490 |
| Change ($) | 0.007 |
| Change (%) | 1.37% |
| Day's Open | 0.500 |
| Day's Range | 0.490 - 0.505 |
| Day's Volume | 4,796,068 |
| 52-Week Range | 0.260 - 1.270 |
More Stats
| Market Cap | 76.13M |
| Enterprise Value | 73.28M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 132.94M |
| Float | n/a |
| EPS (basic) | -0.40 |
| EPS (diluted) | -0.52 |
| FCF / Share | -0.27 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 7.34M |
| Short Ratio | 2.01 |
| Short % of Float | n/a |
| Beta | 1.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 10.42 |
| PB Ratio | 5.10 |
| Revenue | 7.30M |
| Operating Income | -34.60M |
| Net Income | -37.28M |
| Free Cash Flow | -35.72M |
| Net Cash | 2.85M |
| Net Cash / Share | 0.02 |
| Gross Margin | 46.03% |
| Operating Margin | -473.82% |
| Profit Margin | -510.40% |
| FCF Margin | -489.07% |
| ROA | -68.24% |
| ROE | -1,021.64% |
| ROIC | -604.10% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | 10.13 | 12.00 | 9.51 | 6.79 |
| Revenue Growth | -15.59% | 26.26% | 39.93% | - |
| Gross Profit | 3.36 | 3.29 | 3.47 | 3.21 |
| Operating Income | -25.87 | -20.42 | -23.22 | -21.17 |
| Net Income | -29.82 | -18.50 | -23.37 | -18.85 |
| Shares Outstanding | 14.98 | 7.08 | 2.70 | 60.32 |
| Earnings Per Share | -1.99 | -2.61 | -8.65 | -312.46 |
| Operating Cash Flow | -29.53 | -19.94 | -20.82 | -23.50 |
| Capital Expenditures | -0.06 | -0.33 | -1.02 | -1.35 |
| Free Cash Flow | -29.59 | -20.28 | -21.84 | -24.85 |
| Cash & Equivalents | 17.31 | 16.52 | 1.02 | 5.25 |
| Total Debt | 20.09 | 9.03 | 6.73 | 6.63 |
| Net Cash / Debt | -2.77 | 7.49 | -5.71 | -1.38 |
| Assets | 30.21 | 24.80 | 10.15 | 14.79 |
| Liabilities | 26.59 | 14.67 | 17.36 | 16.63 |
| Book Value | 3.61 | 10.14 | -50.23 | -27.26 |
Company Profile
Company Details
| Full Name | BioNano Genomics, Inc. |
| Country | United States |
| Employees | 97 |
| CEO | R. Erik Holmlin |
Stock Information
| Ticker Symbol | BNGO |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: BNGO |
| IPO Date | August 21, 2018 |
Description
Bionano Genomics operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.